Company
Syremis Therapeutics
Developing novel medicines to make a profound impact on mental health care
Also known as Syremis, Syremis Therapeutics Ltd.
- Status
- Operatingas of 2026-09-17
- Business model
- B2B
- Legal name
- Syremis Therapeutics Ltd.
- syremis.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- Press page (opens in a new tab)
- Careers (opens in a new tab)
Claim, correct or request removal
Record updated 28 September 2026
About
Syremis Therapeutics is a clinical-stage biopharmaceutical company developing novel medicines to make a profound impact on the treatment of mental health. The company’s neuropsychiatric pipeline is rooted in emerging and clinically validated mechanisms, including muscarinic M1/M4 agonism and next-generation NMDA antagonism.
Funding snapshot
- Total raised
- $165MSum of rounds, as of 2026-09-17Source (opens in a new tab)
- Latest round
- Undisclosed, $165M2025-12-18
Funding rounds
- Round, 2025
- $165M2025-12-18, Company stated
Products
- Web
- ST-901
- Web
- ST-905
Loading relationship preview